Terminology & definitions
NeuromarkR™
NeuromarkR™ is Neurotype Inc.'s investigational EEG-based platform for characterizing cue-induced neural responses in substance use disorder (SUD) and opioid use disorder (OUD) care and research contexts. The name is a stylized contraction of 'neural biomarker,' reflecting the platform's focus on EEG-derived event-related potential (ERP) signals as objective, quantifiable measures of cue reactivity. NeuromarkR™ is investigational and is not cleared or approved for diagnostic use.
What it means
- An investigational clinical assessment platform that uses EEG to measure event-related potential (ERP) signals — particularly cue-induced neural responses such as the late positive potential (LPP) and P300 — that may inform clinical decision-making in SUD and OUD care.
- A decision support tool designed for use within clinically supervised settings as part of a broader measurement-based care approach, not as a stand-alone diagnostic instrument.
What it does not mean
- NeuromarkR™ is unrelated to 'NEUROMARK' or 'Neuromark' — procedural or device names associated with rhinology and ENT practice, including posterior nasal nerve ablation treatments for chronic rhinitis. Search results for nasal or sinus procedures using those names refer to an entirely different entity.
- 'NeuromarkR™' is distinct from the generic scientific term 'neuromarker' (sometimes written as 'neuro-marker'), used broadly across neuroscience literature to refer to any neural signal with potential biomarker properties. NeuromarkR™ is a specific Neurotype platform, not a category descriptor.
- NeuromarkR™ does not imply FDA clearance, approval, or authorization. Its investigational status means it is evaluated in research and development contexts and is not deployed as a cleared clinical diagnostic tool.
Relationship to Neurotype Inc.
NeuromarkR™ is Neurotype Inc.'s primary investigational product platform. It is designed to provide clinicians and researchers with objective, EEG-derived measures of cue reactivity that can complement self-report and clinical observation in SUD and OUD care and research.
Related clinical resources
- How can cue-reactivity biomarkers support assessment / clinical decision support (CDS) in OUD care?
- What EEG-derived ERP/VEP biomarkers are most predictive of relapse risk in substance use disorders?
- What is the difference between self-reported craving and biomarker-based craving assessment?
- How should clinicians interpret changes in craving biomarkers across treatment?
- Which patients are most appropriate for EEG-based craving assessment in clinical or research settings?
